The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

• Published in: Alzheimer's & dementia Vol. 13; no. 5; pp. 561 - 571
• Main Authors: Weiner, Michael W, Veitch, Dallas P, Aisen, Paul S, Beckett, Laurel A, Cairns, Nigel J, Green, Robert C, Harvey, Danielle, Jack, Clifford R, Jagust, William, Morris, John C, Petersen, Ronald C, Salazar, Jennifer, Saykin, Andrew J, Shaw, Leslie M, Toga, Arthur W, Trojanowski, John Q
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2017; Elsevier
• Subjects: 60 APPLIED LIFE SCIENCES; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - physiopathology; Alzheimer's disease; Amyloid phenotyping; Biomarkers - cerebrospinal fluid; Brain - diagnostic imaging; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Clinical Trials as Topic; Disease Progression; Functional connectivity; Humans; Magnetic Resonance Imaging; Neuroimaging; Neurology; Positron-Emission Tomography; Radionuclide Imaging; Tau imaging; Tau imaging; Brain Health Registry; Functional connectivity; Clinical trial biomarkers; Amyloid phenotyping; Centiloid method; Alzheimer's disease
• ISSN: 1552-5260; 1552-5279
• DOI: 10.1016/j.jalz.2016.10.006

Abstract Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.